EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis and Antidiabetic Activity of Novel Pyrrole‐3‐Carboximidamide Derivatives as Dipeptidyl Peptidase‐4 Inhibitors

Hossein Fasihi Dastjerdi, Nima Naderi, Amir Garmabdari, Manijeh Nematpour, Melika Ebrahimi, Samaneh Hosseinpoor, Fatemeh Saberinasab, Zahra Sheikholislam, Omid Hosseini, Elham Rezaee, Sayyed Abbas Tabatabai iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Hossein Fasihi Dastjerdi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents, Drug Design, Diabetes Mellitus, Experimental. Die Arbeit nennt 27 Literaturangaben. Gefördert von: This study was supported by the research council of the School of Pharmacy, Shahid Beheshti University of Medical Sciences. [Grant No. 24008]..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, and dipeptidyl peptidase‐4 (DPP‐4) inhibitors have emerged as an effective therapeutic option. A new series of pyrrole‐3‐carboximidamide derivatives was designed, synthesized, and evaluated as DPP‐4 inhibitors. Most of the synthesized compounds exhibited favorable inhibitory activity against the DPP‐4 enzyme, and compounds 5f and 5g were found to be the most potent inhibitors with IC₅₀ values of 12.19 and 23.08 nM, respectively. In vivo studies in diabetic Wistar rats showed that daily administration of compound 5g for 2 weeks resulted in a significant decrease in blood glucose compared with the control group. Moreover, compound 5g was effective in reducing plasma glucose in an acute oral glucose tolerance test in NMRI mice. The antiglycemic effects of compound 5g were comparable with standard treatment by sitagliptin, with no effect on normoglycemic rats. Both the in vitro and in vivo antidiabetic properties suggest that compound 5g could be considered a promising candidate for development as an antidiabetic medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsDrug DesignDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2PyrrolesAnimalsRats, WistarStructure-Activity RelationshipMiceRatsMaleBlood GlucoseDipeptidyl Peptidase 4Molecular StructureGlucose Tolerance TestHumansDose-Response Relationship, Drug

Stichwörter der Autor:innen

antidiabeticcarboximidamidedipeptidyl peptidase‐4dockinginhibitor

Substanzen

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsPyrrolesBlood GlucoseDipeptidyl Peptidase 4

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
  • Central Research Laboratories, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Sayyed Abbas Tabatabai

Förderung

  • This study was supported by the research council of the School of Pharmacy, Shahid Beheshti University of Medical Sciences. [Grant No. 24008].

Zitieren

APA

Dastjerdi, H. F., Naderi, N., Garmabdari, A., Nematpour, M., Ebrahimi, M., Hosseinpoor, S., Saberinasab, F., Sheikholislam, Z., Hosseini, O., Rezaee, E., & Tabatabai, S. A. (2025). Design, Synthesis and Antidiabetic Activity of Novel Pyrrole‐3‐Carboximidamide Derivatives as Dipeptidyl Peptidase‐4 Inhibitors. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70077

Vancouver

Dastjerdi HF, Naderi N, Garmabdari A, Nematpour M, Ebrahimi M, Hosseinpoor S, et al. Design, Synthesis and Antidiabetic Activity of Novel Pyrrole‐3‐Carboximidamide Derivatives as Dipeptidyl Peptidase‐4 Inhibitors. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70077

BibTeX
@article{Dastjerdi2025,
  author = {Dastjerdi, Hossein Fasihi and Naderi, Nima and Garmabdari, Amir and Nematpour, Manijeh and Ebrahimi, Melika and Hosseinpoor, Samaneh and Saberinasab, Fatemeh and Sheikholislam, Zahra and Hosseini, Omid and Rezaee, Elham and Tabatabai, Sayyed Abbas},
  title = {Design, Synthesis and Antidiabetic Activity of Novel Pyrrole‐3‐Carboximidamide Derivatives as Dipeptidyl Peptidase‐4 Inhibitors},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70077}
}
Kostenlos starten →